Capula Management’s Health Catalyst HCAT Stock Holding History

Capula Management’s Portfolio HCAT Stock Details HCAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-6,301	Closed	-$315K	–	442
2021 Q3	$315K	Buy	+6,301	New	+$344K	﹤0.01%	694

Other funds holding HCAT

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Riverbridge Partners Minneapolis, Minnesota $3.58B AUM 4.02% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $61.9B AUM 29.81% 1-Year Est. Return

Capula Management's HCAT Position: Q4 2021 in Review

Capula Management sold out of Health Catalyst (HCAT) in Q4 2021, closing a stake of 6,301 shares — an estimated $315K sold.

Capula Management first reported a position in HCAT in Q3 2021 and held it in 1 quarter. The position peaked at $315K in Q3 2021. 186 funds tracked by Wall St. Rank hold HCAT as of Q4 2021.

Capula Management reported no remaining Health Catalyst position as of Q4 2021 after selling out during the quarter.
Capula Management sold 6,301 Health Catalyst shares in Q4 2021, an estimated $315K.
Capula Management first reported a position in Health Catalyst in Q3 2021 and held it in 1 quarter.
Capula Management's Health Catalyst position peaked at $315K in Q3 2021.
186 funds tracked by Wall St. Rank held Health Catalyst as of Q4 2021.

Based on Capula Management's 13F filing for Q4 2021, filed 14 Feb 2022.